Main Uses and Indications

Retaphyl is a medication primarily used for the long-term management and maintenance of respiratory conditions characterized by airway obstruction. It belongs to a class of drugs known as xanthines, which act as bronchodilators to help keep the airways open.

Chronic Obstructive Pulmonary Disease (COPD)

Retaphyl is used to treat symptoms associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It helps to reduce the frequency and severity of shortness of breath by relaxing the smooth muscles in the lungs, facilitating easier airflow.

Asthma Management

For individuals with asthma, Retaphyl serves as a maintenance treatment to prevent symptoms such as wheezing and chest tightness. It is typically utilized in patients whose symptoms are persistent and require daily medication to maintain lung function.

Benefits and Mechanism of Action

The primary benefit of Retaphyl is its ability to provide prolonged bronchodilation, which contributes to improved respiratory stability throughout the day and night.

Airway Relaxation

The active component works by inhibiting specific enzymes and blocking receptors that contribute to the constriction of the bronchial tubes. This relaxation of the respiratory muscles allows the airways to widen, making it easier for the patient to breathe.

Anti-inflammatory Effects

In addition to its role as a bronchodilator, Retaphyl may exhibit mild anti-inflammatory properties. By reducing the inflammatory response within the airways, it can help decrease sensitivity to environmental triggers and prevent the progression of respiratory distress.

Diaphragmatic Strength

Some clinical observations suggest that the medication may help strengthen the diaphragm, the primary muscle used for breathing. This can be particularly beneficial for patients with chronic lung conditions who experience muscle fatigue during respiratory exertion.

Regulatory References

1. NIH MedlinePlus overview

The use of Retaphyl (Choline Theophyllinate) is defined by official regulatory criteria, which outline absolute prohibitions and conditional use requirements across different patient populations.

Contraindications and Absolute Prohibitions

Use of this medicine is absolutely contraindicated in patients with a known hypersensitivity to Theophylline or other Xanthine derivatives. It must also not be used by individuals with certain pre-existing conditions, including active peptic ulcer disease, uncontrolled seizure disorders, or during the acute phase of myocardial infarction.

Age and Physiological Restrictions

Population	Eligibility Status (Regulatory Wording)
Infants (Under 6 months)	Contraindicated
Pregnant/Breastfeeding	Not Recommended (unless benefit strictly outweighs risk)
Older Adults	Use with Caution (due to reduced clearance)

Conditional Use and Comorbidity Caution

Use requires caution and close monitoring in patients with impaired liver function (hepatic impairment), severe cardiac disease (such as arrhythmias or severe hypertension), diabetes mellitus, and hyperthyroidism. These populations may experience altered drug clearance or increased susceptibility to the effects of the medicine.

Retaphyl Interactions with other medicines and products is largely defined by pharmacokinetic interference and specific pharmacodynamic restrictions documented in official government labeling.

The primary interaction domain involves the modulation of drug clearance. Co-administration with certain prescription medicines, such as the CYP1A2 inhibitors Cimetidine and Fluvoxamine, formally increases systemic exposure of Retaphyl and requires appropriate action to manage this change. Conversely, exposure may be formally decreased when co-administered with CYP inducers like Carbamazepine or Rifampin.

Documented pharmacodynamic restrictions include the prohibited co-administration with other Xanthine Derivatives due to the risk of additive toxicity. Furthermore, the use of Non-selective Beta-blockers is noted to pharmacologically antagonize the drug's intended action. Combining Retaphyl with agents like Halothane is officially associated with an increased risk of specific adverse outcomes, such as ventricular arrhythmias.

Interaction constraints extend to substances, as a single large dose of Alcohol is documented to decrease clearance, and Tobacco Smoke is noted to increase clearance. Official regulatory information specifies that elderly patients and those with hepatic impairment have reduced clearance, a population-specific note that amplifies the potential clinical significance of all documented pharmacokinetic interactions. The official profile also cautions against certain food components, including St. John's Wort and Charbroiled Meat, which are reported to alter absorption or blood levels.

Retaphyl's molecular effect is achieved through three distinct, simultaneous actions on cellular and central physiological systems, targeting key enzymes, receptors, and genetic regulation processes.

Enzyme Modulation and Airway Relaxation

This mechanistic domain involves the nonselective inhibition of Phosphodiesterase (PDE) enzymes, particularly PDE-III and PDE-IV, within smooth muscle cells. By blocking the enzymes responsible for breaking down a critical messenger molecule (cAMP), the drug causes the concentration of this messenger to rise, initiating a cascade that leads to the relaxation of airway smooth muscle, which results in the decreased tone of smooth muscle tissue.

Receptor Blockade and Central Stimulation

The drug acts as a nonselective antagonist of Adenosine Receptors throughout the body, including those in the central nervous system. By blocking the normal inhibitory signaling of adenosine, this mechanism leads to the potentiation of central respiratory drive in the brain and modifies the contractile force of respiratory muscles.

Gene Regulation and Cellular Modulation

Retaphyl also modulates biological processes by restoring the activity of Histone Deacetylase 2 (HDAC2), an enzyme often suppressed during inflammation. This action promotes the cellular process of "turning off" specific genes responsible for creating inflammatory mediators, which results in the suppression of pro-inflammatory gene transcription and mediator release.

Administration Guidelines for Retaphyl (Choline Theophyllinate)

Retaphyl is a trade name for Choline Theophyllinate, an oral drug used as a theophylline source. The administration protocol is centered on achieving and maintaining a specific therapeutic concentration of theophylline in the blood, often between 10 and 15 mcg/mL, as established in clinical protocols.

Route of Administration and Forms

Category	Instructions
Route of Administration	Primarily Oral administration for maintenance, utilizing liquid or solid forms. Intravenous use is reserved for acute settings.
Standard Adult Dose Range	The total daily dose is typically 400 to 600 mg (anhydrous theophylline equivalent), with an absolute maximum of 600 mg/day for most adults.
Frequency Pattern	Immediate-release formulations are administered in divided doses every 6 to 8 hours. Extended-release forms are taken once or twice daily (q12h or q24h) to maintain steady blood levels.

Procedural Requirements and Special Conditions

The dosage requires individualization and titration, starting low and being adjusted in small increments, often not sooner than three-day intervals, to reach the desired concentration. This titration process must be guided by periodic serum theophylline concentration measurements, which should be taken frequently during treatment initiation and at 6 to 12-month intervals during long-term maintenance.

Extended-release solid dosage forms must be swallowed whole to prevent the immediate release of the entire dose. Patients should take doses at the same time each day for consistency. Lower maximum doses (e.g., 400 mg/day) are specified for older adults, reflecting altered drug clearance in this population.

Research evidence / Overview of Studies for Retaphyl (Choline Theophyllinate)

Evidence from Trials for Chronic Obstructive Pulmonary Disease (COPD)

Research related to the use of Retaphyl (Choline Theophyllinate) in patients with COPD has included Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies evaluated the compound in the context of chronic airflow limitation as a maintenance or add-on treatment. Researchers examined key outcomes related to physical discomfort and functional imbalance, such as monitoring objective measures of lung function, like the Forced Expiratory Volume in 1 second ( FEV1). Trials also monitored outcomes describing episodic or acute changes, specifically tracking the overall rate of COPD exacerbations (periods of symptom worsening).

However, certainty remains low regarding outcomes related to systemic or functional imbalance in long-term follow-up due to the age of some primary evidence and the modest sample sizes used in certain studies. The overall evidence quality varies across studies, and comparative evidence against other treatment approaches is lacking in recent data.

---

Evidence from Trials for Chronic Asthma

For chronic asthma, the evidence base is drawn primarily from RCTs and comparative studies. Research explored the compound as a long-term maintenance or add-on therapy for persistent symptoms. Studies monitored patient-reported outcomes describing perceived discomfort, such as documenting the frequency of symptoms, particularly those occurring overnight. Researchers also monitored objective measures of functional capacity, such as Peak Expiratory Flow (PEF) rates, and documented the use of short-acting rescue inhalers.

Findings describe patterns observed in the studies related to the objective function of the airways. However, despite the historical research base, data for certain groups remain insufficient, and certainty regarding its precise placement in modern treatment strategies appears to be limited.

---

What is Still Uncertain About the Research Base

The research highlights key limitations. For instance, the modest sample sizes of some primary trials mean the generalizability of certain findings is not fully established. Comparative evidence is lacking in trials that match the compound directly against the newest first-line inhaled therapies for both asthma and COPD. Furthermore, research provides context but not individual predictions, and the evidence base contributes to understanding symptom patterns but does not determine whether an individual will respond similarly.

Key Studies & References

1. THEOPHYLLINE Extended Release Capsules, USP - Full Prescribing Information
2. Chronic Use of Theophylline and Mortality in Chronic Obstructive Pulmonary Disease: A Meta-analysis

Common questions about Retaphyl (FAQ)

Q: What is the main reason a doctor would prescribe Retaphyl?

A: Retaphyl is officially indicated for managing the symptoms and reversible airflow issues associated with chronic asthma and other chronic lung diseases. These conditions include emphysema and chronic bronchitis. Official labeling states its main purpose is to help treat these respiratory issues.

Q: Is it normal to feel tired when starting Retaphyl?

A: Official product information lists insomnia (trouble sleeping) and restlessness as common side effects affecting the nervous system. Tiredness or drowsiness, however, is not typically listed among the common effects in regulatory summaries for this medication.

Q: What age group is Retaphyl generally studied for?

A: Clinical studies and pharmacokinetic data often focus on adult patients to determine how the body processes the medication. However, official regulatory documents also contain specific information, including required dose adjustments, for use in children and older adults.

Q: What organs does Retaphyl primarily affect?

A: The medication's function involves several body systems. Official information describes its primary actions in the respiratory airways (by relaxing muscle to aid breathing) and the central nervous system (which can lead to stimulation). Its effects are also described in relation to the diaphragm muscle.

Q: How does the drug's purpose relate to the mechanism of action described in 'How Retaphyl works'?

A: The general purpose of improving airflow is directly connected to the drug's mechanism of action. The key effect is the relaxation of smooth muscle in the airways, which is a process known as bronchodilation. This action helps to open the air passages in the lungs.

Q: Why is it important to know about Retaphyl's interactions?

A: Knowing about interactions is important because Retaphyl has a narrow therapeutic range, which means there is a small difference between an effective concentration and a potentially toxic one. Interactions with other substances can significantly change the drug's concentration in the blood, potentially increasing the risk of severe side effects or toxicity.

Q: Is Retaphyl considered a controlled substance?

A: The active component of Retaphyl, theophylline, is not currently classified as a controlled substance. This means it is not regulated under the U.S. Controlled Substances Act or similar international regulatory schedules.

Q: How quickly is Retaphyl expected to start working?

A: Official regulatory data indicates that for the immediate-release form, the medication typically reaches its peak concentration in the blood around 1 to 2 hours after being taken. This is when the medication is exerting its maximum effect.

Q: What happens if I stop taking Retaphyl suddenly?

A: Regulatory guidance often suggests that for long-term use, the drug be gradually weaned rather than stopped suddenly, especially if it has been used for a long time. Abrupt discontinuation could potentially lead to a worsening of underlying respiratory symptoms.

Q: Is Retaphyl available over the counter?

A: According to regulatory information, the active component is classified as a prescription-only medication. This means the drug is not available for purchase over the counter.

Q: Does Retaphyl cause weight gain?

A: Weight gain is not listed among the commonly reported side effects in official product labeling. Common side effects are usually related to the nervous system, gastrointestinal system, and heart rate.

Q: Can Retaphyl interact with common pain relievers like ibuprofen?

A: Official documents do not typically list common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen as direct inhibitors that alter the drug's concentration. However, regulatory bodies note that the use of NSAIDs requires caution for individuals with pre-existing asthma.

Q: Are there different strengths of Retaphyl available?

A: Yes, the active component of the drug is available in several extended-release forms. These typically include various tablet and capsule strengths, such as 100 mg, 200 mg, 300 mg, and 400 mg equivalent doses.

Q: Is there a generic version of Retaphyl?

A: The active ingredient, theophylline, is widely available as a generic product. Regulatory agencies, such as the FDA, have approved generic formulations that are considered bioequivalent to the branded versions.

Q: Is Retaphyl typically taken with or without food?

A: Official product labeling states that this medicine can be taken with or without food. However, regulatory information notes that the timing when the drug reaches its maximum concentration in the blood may vary slightly depending on whether it is taken on an empty stomach or with a meal.

Q: Does Retaphyl carry a Boxed Warning in official drug information?

A: Yes, some US formulations of the active component may carry a Boxed Warning (the strongest regulatory caution). This warning is present due to the potential for serious and potentially life-threatening side effects, specifically seizures and severe cardiac arrhythmias (irregular heart rhythms).

Q: What happens if I miss a dose of Retaphyl?

A: Official patient information describes that a missed dose is typically taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the information generally states that the missed dose should be skipped to prevent two doses from being taken too close together.

Q: Do studies suggest Retaphyl is habit-forming?

A: The active component of this medication is not listed in official regulatory documents as having a potential for abuse or dependence.

Q: What is the maximum duration of use for Retaphyl mentioned in official labeling?

A: Regulatory guidelines describe this medicine as being used for the long-term management of chronic respiratory conditions. Official labeling does not typically specify an absolute maximum duration for how long the drug can be used.

Q: Does taking Retaphyl affect my ability to drive?

A: Regulatory information notes central nervous system side effects such as restlessness, headache, and tremor. The potential impact of these effects is a safety consideration before driving or operating heavy machinery.

Q: Can Retaphyl be taken with a common cold medicine?

A: Many common cold medicines contain ingredients that are classified as sympathomimetics. Regulatory documents warn that combining these agents with the active component of Retaphyl may increase the risk of certain cardiovascular effects.

Q: Is Retaphyl related to any recalls in the past?

A: Regulatory notices have documented instances of voluntary market withdrawals (recalls) for specific batches of the extended-release formulation containing theophylline. These withdrawals typically occur due to quality control issues, such as tablets not dissolving correctly.

Q: Does Retaphyl contain lactose or gluten?

A: Official labeling for some extended-release tablet formulations explicitly lists inactive ingredients such as lactose monohydrate or anhydrous lactose. For specific sensitivities, checking the full ingredient list for the specific formulation is standard guidance.

Q: How is Retaphyl typically discontinued?

A: Medical consensus suggests that for long-term use, the drug is typically gradually weaned rather than stopped abruptly. This process is recommended to help prevent a potential worsening of underlying respiratory symptoms.

Storage and Disposal Requirements for Retaphyl

The storage and disposal of Retaphyl (Choline Theophyllinate) must follow explicit conditions set by regulatory labeling to maintain the product's integrity and ensure safety.

Required Storage Conditions

The medication must be stored at room temperature, with requirements often stating storage below 25 C. The product must be protected from light and moisture exposure. A mandatory requirement for safety is to store Retaphyl out of the sight and reach of children.

Disposal Instructions

Official disposal rules prohibit discarding unused or expired medication in wastewater (e.g., flushing down the toilet) or placing it in household garbage. Users are instructed to consult a pharmacist to arrange proper disposal according to local pharmaceutical waste regulations.